Travere Therapeutics Remains Attractive Despite 'Disappointing' Halt on Pegtibatinase Trial, Wedbush Says
Travere Therapeutics Remains Attractive Despite 'Disappointing' Halt on Pegtibatinase Trial, Wedbush Says
韦德布什表示,尽管佩格替巴汀酶试验被"令人失望"地停止,Travere Therapeutics仍然具有吸引力。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册